Akeso Broadens Ivonescimab Agreement With Summit
Company Announcements

Akeso Broadens Ivonescimab Agreement With Summit

Akeso, Inc. (HK:9926) has released an update.

Akeso, Inc. has expanded its license agreement with Summit Therapeutics Inc., now including exclusive development and commercialization rights for its bi-specific antibody, ivonescimab, in additional regions such as Central and South America, the Middle East, and Africa. The amendment promises Akeso up to $70 million in upfront and milestone payments, plus sales royalties. Ivonescimab, which has been approved in China for certain lung cancer treatments, is undergoing multiple clinical trials for various indications.

For further insights into HK:9926 stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App